UB Paderborn / Katalog / Suche / in CDI

Gerätesatz Auf- und Abseilgerät

2nd ed., 2024

Link zum Volltext

Verfügbarkeit prüfen

Absturzsicherung

Mezger, Jörg

3rd ed., 2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1227-1234

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Journal of clinical oncology, 2014-12, Vol.32 (35), p.4012-4019

2014

Link zum Volltext

Verfügbarkeit prüfen

Exemption: Promyelocytic Leukemia

Deutsches Ärzteblatt international, 2015-07, Vol.112 (29-30), p.505-505

Mezger, Jörg

2015

Link zum Volltext

Verfügbarkeit prüfen

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The lancet oncology, 2015-03, Vol.16 (3), p.328-337

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical presentation and diagnosis of adult patients with non‐Hodgkin lymphoma in Sub‐Saharan Africa

British journal of haematology, 2020-07, Vol.190 (2), p.209-221

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)

Journal of thoracic oncology, 2010-12, Vol.5 (12), p.1970-1976

2010

Link zum Volltext

Verfügbarkeit prüfen

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

British journal of cancer, 2017-09, Vol.117 (6), p.757-766

2017

Link zum Volltext

Verfügbarkeit prüfen

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

The Lancet (British edition), 2015-04, Vol.385 (9976), p.1418-1427

2015

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-08, Vol.26 (24), p.3979-3986

2008

Link zum Volltext

Verfügbarkeit prüfen

EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study

Cancer epidemiology, biomarkers & prevention, 2015-08, Vol.24 (8), p.1254-1261

2015

Link zum Volltext

Verfügbarkeit prüfen

Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy

Deutsche medizinische Wochenschrift (1946), 2017-01, Vol.142 (2), p.111

2017

Link zum Volltext

Verfügbarkeit prüfen

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Oncology research and treatment, 2016-09, Vol.39 (9), p.539-547

2016

Link zum Volltext

Verfügbarkeit prüfen

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Blood, 2017-12, Vol.130, p.2618-2618

2017

Link zum Volltext

Verfügbarkeit prüfen

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Blood, 2016-12, Vol.128 (22), p.2815-2815

2016

Link zum Volltext

Verfügbarkeit prüfen

Exemption: Promyelocytic Leukemia

Deutsches Ärzteblatt international, 2015-07

Mezger, Jörg

2015

Link zum Volltext

Verfügbarkeit prüfen

Open, Randomized, Phase II Study of Single-Agent Gemcitabine and Docetaxel as First- and Second-Line Treatment in Patients with Advanced Non–Small-Cell Lung Cancer

Clinical lung cancer, 2007, Vol.8 (4), p.245-251

2007

Link zum Volltext

Verfügbarkeit prüfen

Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer

Clinical lung cancer, 2005-11, Vol.7 (3), p.208-214

2005

Link zum Volltext

Verfügbarkeit prüfen

O-218 Single-agent Gemcitabine (G) and Docetaxel (D) given sequentially every 3 weeks in advanced NSCLC: Final results and quality of life assessment of a randomised phase II study show effective treatment

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S64-S64

2003

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Gerätesatz Auf- und Abseilgerät

Absturzsicherung

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

Exemption: Promyelocytic Leukemia

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort

Clinical presentation and diagnosis of adult patients with non‐Hodgkin lymphoma in Sub‐Saharan Africa

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study

Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Exemption: Promyelocytic Leukemia

Das Feuerwehr-Lehrbuch: Grundlagen - Technik - Einsatz

Open, Randomized, Phase II Study of Single-Agent Gemcitabine and Docetaxel as First- and Second-Line Treatment in Patients with Advanced Non–Small-Cell Lung Cancer

Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer

Das Feuerwehr-Lehrbuch: Grundlagen - Technik - Einsatz

O-218 Single-agent Gemcitabine (G) and Docetaxel (D) given sequentially every 3 weeks in advanced NSCLC: Final results and quality of life assessment of a randomised phase II study show effective treatment

Das Feuerwehr-Lehrbuch: Grundlagen - Technik - Einsatz

Suchergebnisse filtern